[go: up one dir, main page]

NO20052691L - Remedium for overaktiv blaere, omfattende eddiksyreanilidderivat som aktiv ingrediens. - Google Patents

Remedium for overaktiv blaere, omfattende eddiksyreanilidderivat som aktiv ingrediens.

Info

Publication number
NO20052691L
NO20052691L NO20052691A NO20052691A NO20052691L NO 20052691 L NO20052691 L NO 20052691L NO 20052691 A NO20052691 A NO 20052691A NO 20052691 A NO20052691 A NO 20052691A NO 20052691 L NO20052691 L NO 20052691L
Authority
NO
Norway
Prior art keywords
bladder
remedy
test
active ingredient
rat
Prior art date
Application number
NO20052691A
Other languages
English (en)
Other versions
NO20052691D0 (no
NO334948B1 (no
Inventor
Tatsuya Maruyama
Toshiyuki Takasu
Shuichi Sato
Masashi Ukai
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052691(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO20052691D0 publication Critical patent/NO20052691D0/no
Publication of NO20052691L publication Critical patent/NO20052691L/no
Publication of NO334948B1 publication Critical patent/NO334948B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Remedium for overaktiv blære, omfattende som aktiv ingrediens (R)-2-(2-aminotiazol-4-yl)-4'-[2[(2-hydroksy-2-fenyletyl)amino]etyl]eddiksyreanilid eller salt av dette, viser en potent blærerelakserende virkning i "test for relaksasjon av glatte muskler i isolert rotteblære", doseavhengig reduksjon i kontraksjonsfrekvensen ved rytmiske blærekontraksjoner i "test for måling av rytmisk blærekontraksjon hos rotte", og forlenger urineringsintervallene i "test for måling av urineringsfunksjon med overaktiv blære forårsaket av syklofosfamid i rotte som modell". Disse virkninger gjør forbindelsen over anvendelig som et remedium for overaktiv blære.
NO20052691A 2002-11-07 2005-06-06 Sammensetning for anvendelse ved terapeutisk behandling av overaktiv blære, omfattende eddiksyreanilinderivat som aktiv ingrediens NO334948B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja) 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Publications (3)

Publication Number Publication Date
NO20052691D0 NO20052691D0 (no) 2005-06-06
NO20052691L true NO20052691L (no) 2005-07-15
NO334948B1 NO334948B1 (no) 2014-08-04

Family

ID=32310425

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052691A NO334948B1 (no) 2002-11-07 2005-06-06 Sammensetning for anvendelse ved terapeutisk behandling av overaktiv blære, omfattende eddiksyreanilinderivat som aktiv ingrediens
NO2015001C NO2015001I2 (no) 2002-11-07 2015-01-19 Mirabegron eller et salt derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2015001C NO2015001I2 (no) 2002-11-07 2015-01-19 Mirabegron eller et salt derav

Country Status (28)

Country Link
US (5) US7750029B2 (no)
EP (1) EP1559427B1 (no)
JP (1) JP3815496B2 (no)
KR (1) KR100967070B1 (no)
CN (1) CN100406011C (no)
AT (1) ATE500827T1 (no)
AU (1) AU2003284700B2 (no)
BE (1) BE2013C040I2 (no)
BR (1) BR0316080A (no)
CA (1) CA2503570C (no)
CY (2) CY1111399T1 (no)
DE (1) DE60336334D1 (no)
DK (1) DK1559427T3 (no)
ES (1) ES2360353T3 (no)
FR (1) FR13C0032I2 (no)
HU (1) HUS1300027I1 (no)
IL (1) IL168121A (no)
LU (1) LU92218I2 (no)
MX (1) MXPA05004925A (no)
NL (1) NL300599I2 (no)
NO (2) NO334948B1 (no)
NZ (1) NZ539577A (no)
PL (1) PL211687B1 (no)
PT (1) PT1559427E (no)
RU (1) RU2321401C2 (no)
SI (1) SI1559427T1 (no)
WO (1) WO2004041276A1 (no)
ZA (1) ZA200503510B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
JP5263170B2 (ja) * 2007-11-02 2013-08-14 アステラス製薬株式会社 過活動膀胱治療用医薬組成物
CA2709727A1 (en) * 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2363397A4 (en) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co NEW THERAPEUTIC AGENT USEFUL FOR SYMPTOM OF LOWER URINARY TRACT
US8586760B2 (en) * 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US8877214B2 (en) * 2010-03-29 2014-11-04 Astellas Pharma Inc. Pharmaceutical composition for modified release
ES2665467T3 (es) * 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
EP2709993A4 (en) 2011-05-18 2015-02-25 Reddys Lab Ltd Dr AMORPHIC MIRABEGRON AND METHOD FOR CRYSTALLINE FORMS OF MIRABEGRON
WO2013147134A1 (ja) 2012-03-30 2013-10-03 アステラス製薬株式会社 ミラベグロン含有医薬組成物
US20150306090A1 (en) 2012-08-31 2015-10-29 Astellas Pharma Inc. Orally administered medical composition
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
KR20160033220A (ko) * 2013-07-23 2016-03-25 알러간, 인코포레이티드 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
CA2967390A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
SI3360866T1 (sl) 2017-02-14 2019-04-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Mirabegronska predzdravila
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP3636256B1 (en) 2017-05-31 2024-07-03 SBI Pharmaceuticals Co., Ltd. Prophylactic or therapeutic agent for hyperactive bladder
CN110869022A (zh) 2017-06-06 2020-03-06 乌洛万特科学有限公司 使用维贝隆以治疗膀胱过度活动症
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
AU2019393372B2 (en) 2018-12-05 2025-08-21 Sumitomo Pharma Co., Ltd Vibegron for the treatment of overactive bladder symptoms
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2026010595A1 (en) 2024-07-04 2026-01-08 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A modified release tablet composition comprising mirabegron

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
HUT69285A (en) 1993-04-26 1995-09-28 Fujisawa Pharmaceutical Co Ethanolamine derivatives, pharmaceutical compns. contg. them and process to prepare the sald compds.
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
WO1998007445A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
CA2302496C (en) * 1997-08-28 2009-12-08 Afferon Corporation Urinary incontinence therapy
EP1028111B1 (en) 1997-10-17 2004-05-12 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof
ATE250570T1 (de) 1997-12-18 2003-10-15 Kissei Pharmaceutical Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
KR100576131B1 (ko) * 1998-04-14 2006-05-03 깃세이 야쿠힌 고교 가부시키가이샤 2­메틸프로피온산유도체 및 그 유도체를 함유하는의약조성물
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
EP1218536A2 (en) * 1999-02-12 2002-07-03 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
EP1258253A1 (en) 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) * 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
WO2006102029A2 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence

Also Published As

Publication number Publication date
CY2013023I2 (el) 2015-10-07
NZ539577A (en) 2007-06-29
NO20052691D0 (no) 2005-06-06
NO2015001I1 (no) 2015-01-19
ES2360353T3 (es) 2011-06-03
SI1559427T1 (sl) 2011-06-30
WO2004041276A1 (ja) 2004-05-21
USRE44872E1 (en) 2014-04-29
BE2013C040I2 (no) 2023-03-07
DE60336334D1 (de) 2011-04-21
NO334948B1 (no) 2014-08-04
EP1559427A4 (en) 2007-05-30
CA2503570A1 (en) 2004-05-21
CA2503570C (en) 2011-04-19
MXPA05004925A (es) 2005-08-18
LU92218I2 (fr) 2014-01-07
LU92218I9 (no) 2019-01-17
NO2015001I2 (no) 2015-01-26
AU2003284700B2 (en) 2009-05-28
PT1559427E (pt) 2011-05-27
IL168121A (en) 2011-12-29
CN1711085A (zh) 2005-12-21
JP3815496B2 (ja) 2006-08-30
US7750029B2 (en) 2010-07-06
US8835474B2 (en) 2014-09-16
US20090093529A1 (en) 2009-04-09
BR0316080A (pt) 2005-09-27
DK1559427T3 (da) 2011-04-26
CY2013023I1 (el) 2015-10-07
KR100967070B1 (ko) 2010-07-01
EP1559427B1 (en) 2011-03-09
ZA200503510B (en) 2006-12-27
CY1111399T1 (el) 2015-08-05
PL376771A1 (pl) 2006-01-09
FR13C0032I2 (fr) 2014-03-07
KR20050072809A (ko) 2005-07-12
NL300599I2 (no) 2017-01-03
US20060115540A1 (en) 2006-06-01
PL211687B1 (pl) 2012-06-29
US20110230530A1 (en) 2011-09-22
HUS1300027I1 (hu) 2016-08-29
RU2005117367A (ru) 2006-01-20
JPWO2004041276A1 (ja) 2006-03-02
ATE500827T1 (de) 2011-03-15
EP1559427A1 (en) 2005-08-03
CN100406011C (zh) 2008-07-30
FR13C0032I1 (no) 2013-08-09
AU2003284700A1 (en) 2004-06-07
RU2321401C2 (ru) 2008-04-10

Similar Documents

Publication Publication Date Title
NO20052691L (no) Remedium for overaktiv blaere, omfattende eddiksyreanilidderivat som aktiv ingrediens.
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
NO20044866L (no) Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer
DK1542997T3 (da) Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
WO2002083111A3 (en) Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
IL217962A (en) Useful intermediate in the preparation of a history of n - [2- (2-pyridinyl) ethyl] carboxamide
ATE556061T1 (de) Therapeutisches oder prophylaktisches mittel gegen multiple sklerose
NO20065904L (no) Terapeutiske forbindelser
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
DK1369419T3 (da) N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf
NO20054607L (no) Nitrogenholdig heterosyklisk derivat som har 2,6-disubstituert styryl
EP1669345A4 (en) ESTER DERIVATIVE AND MEDICAL USE THEREOF
ES2156574B1 (es) Nuevos derivados de tiazolidindiona como agentes antidiabeticos
NO20053715D0 (no) 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk
NO20065873L (no) 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner
DE602007012435D1 (de) Leukämie
ATE172959T1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
NO20076251L (no) Nye DHA derivater og deres anvendelse som medikamenter
EP1650210A4 (en) THERAPEUTIC AGENT AGAINST HYPERKALEMIA AND BONE DISEASE
WO2005016269A3 (en) Methods for treating metabolic syndrome
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
WO2003042188A1 (en) Triazole derivative and medicinal composition containing the same
HK1056410A (en) Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: BETMIGA - MIRABEGRON; REG. NO/DATE: EU/1/12/809/001-014 20130117

Spc suppl protection certif: 2015001

Filing date: 20150119

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: MIRABEGRON ELLER SALTER DERAV; REG. NO/DATE: EU/1/12/809/001-014 20130117

Spc suppl protection certif: 2015001

Filing date: 20150119

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: ASTELLAS PHARMA INC, JP

Spc suppl protection certif: 2015001

MK1K Patent expired